New HPV Vaccine Results
A study released April 21, 2015 by the American Association for Cancer Research found that the HPV vaccine can protect against infection across multiple site on the body, even in women who have been infected in the past.
4186 women between the ages of 18 and 25 were vaccinated with either the HPV 16/18 vaccine or a control Heptatitis A vaccine. The randomized controlled trial sought to determine if the HPV vaccine could protect women against oral, anal, and cervical HPV.
According to an April 21st Tmes article by Alexendra Stifferlin, “efficacy for the vaccine in all three sites was 83% among the women with no evidence of prior HPV exposure and infection, 58% among women with prior HPV exposure, and a 25% among women with active cervical HPV16/18 infection (the percentage was considered nonsignificant).”
Overall, the efficacy of the vaccine in all three sites was 65%, and 91% for two sites. These results support the CDC’s recommendation for women up to age 26, and men up to age 21 to get the vaccine if they did not receive it at a younger age.